
Contents

Preface	ix
Chapter 1. A Description of the Big Bang Model	1
1.1. Red-shift phenomenon in the spectrum of stars and galaxies	2
1.1.1. Doppler effect	2
1.1.2. Doppler–Fizeau effect	5
1.1.3. Doppler shift expression	9
1.2. Theoretical and experimental facts leading to the validation of the Big Bang model.	13
1.2.1. From redshift observation to the “primitive atom” hypothesis	13
1.2.2. From Hubble observations to the discovery of the cosmic microwave background	14
1.3. Brief description of the chronology of the universe’s evolution after the Big Bang	19
1.3.1. From singularity to the era of inflation	20
1.3.2. From baryogenesis to primordial nucleosynthesis	26
1.3.3. From the dark age of the universe to the radiative era	27
1.3.4. Star formation	28
Chapter 2. The Nucleosynthesis Process	33
2.1. Nucleosynthesis	34
2.1.1. Notion of chemical elements	34
2.1.2. Definition, different nucleosynthesis processes	35
2.1.3. Primordial nucleosynthesis	36
2.1.4. Stellar nucleosynthesis	42
2.1.5. Explosive nucleosynthesis	49

2.2. Other important nucleus-forming processes, radionuclides in the environment	53
2.2.1. Triple-alpha reaction, Hoyle state	53
2.2.2. Formation process of compound nuclei, resonance states	55
2.2.3. CNO (Carbon–Nitrogen–Oxygen) cycle	56
2.2.4. Bethe–Weizsäcker cycle	58
2.2.5. Natural and artificial radionuclides in the environment	61
Chapter 3. Radiochronometer Applications in Dating	63
3.1. Carbon-14 dating	64
3.1.1. A brief history of radiocarbon-14 dating	64
3.1.2. Cosmogenic isotopes: the case of carbon-14	66
3.1.3. Radiocarbon-14 in the biosphere	66
3.1.4. Principle of ^{14}C dating	67
3.1.5. Age correction, radiocarbon age and calendar age.	71
3.1.6. Calibrating radiocarbon ages: reasons for calibration?	73
How to calibrate?	73
3.2. Potassium–argon (K–Ar) dating	80
3.2.1. Principle of dating	80
3.2.2. Basic assumptions for the K–Ar radiochronometer	81
3.2.3. Age equation	82
3.2.4. Atmospheric correction.	85
3.2.5. Preparing samples for K–Ar dating	86
3.2.6. Experimental protocols for potassium and argon measurements	88
3.2.7. Overestimation of K–Ar ages	92
3.2.8. Description of the $^{40}\text{Ar}/^{39}\text{Ar}$ dating method.	93
3.3. Lake dating using ^{210}Pb , ^{137}Cs and ^7Be radiochronometers	94
3.3.1. Core drilling system	94
3.3.2. Lead-210 dating: CFCS, CRS and CIC models	96
3.3.3. Nuclear tests, Chernobyl accident	104
3.3.4. Cesium-137 dating	108
3.3.5. ^7Be dating	112
3.4. Uranium–thorium or uranium–lead dating	115
3.4.1. Method principle	115
3.5. Coral dating	117
3.5.1. Uranium-238 decay chain	117
3.5.2. Sampling, mechanical sample preparation	119
3.5.3. Chemical preparation of samples, X-ray diffraction analysis	120
3.5.4. Coral dating using the $^{238}\text{U}/^{230}\text{Th}$ and $^{235}\text{U}/^{231}\text{Pa}$ methods.	121
3.5.5. Coral dating using the $^{233}\text{U}/^{230}\text{Th}$ method.	122
3.5.6. Dating corals and speleothems using $^{234}\text{U}/^{238}\text{U}$ and $^{230}\text{Th}/^{238}\text{U}$ methods.	125

3.6. File on dating archaeological objects	131
3.6.1. General points	131
3.6.2. Choice of dating method(s)	131
3.6.3. Authentication issues	132
3.6.4. Checking the validity of a date inscribed on the work	133
3.6.5. Tracing the history of a manuscript	133
Chapter 4. General Information on Radiopharmaceuticals Used in Nuclear Medicine Imaging	135
4.1. Nuclear medicine	136
4.1.1. Definition, objectives	136
4.1.2. The birth of nuclear medicine	137
4.1.3. Diseases diagnosed in nuclear medicine	142
4.2. Cancer	143
4.2.1. Cell organization in the organism	143
4.2.2. Evolution of cancer cells, tumor	145
4.2.3. Carcinogenesis, metastasis	146
4.2.4. Angiogenesis, vascular endothelial growth factor (VEGF)	148
4.2.5. Tumor angiogenesis	150
4.2.6. Global cancer epidemiology data	152
4.2.7. Cancer control in Senegal	157
4.2.8. Recommendations from cancer organizations	158
4.3. General information on radiopharmaceuticals.	160
4.3.1. Notion of radiopharmaceuticals, specific properties	160
4.3.2. Quality control of radiopharmaceuticals	161
4.3.3. Radiochemical purity, experimental determination methods	162
4.3.4. Thin-layer chromatography applied to the determination of radiochemical purity	164
4.3.5. Determination of radionuclidic purity.	169
4.4. Nuclear medicine imaging techniques: PET and SPECT.	170
4.4.1. Radioisotopes used in nuclear medicine imaging	170
4.4.2. Principle of positron emission tomography (PET)	172
4.4.3. PET scan.	173
4.4.4. PET scan procedure.	174
4.4.5. PET/CT examination	177
4.4.6. Principle of single-photon emission computed tomography	177
4.4.7. Main scintigraphies and their uses.	178
4.5. Appendices on dementia diseases	179
4.5.1. Appendix 1. Alzheimer's disease	179
4.5.2. Appendix 2. Lewy body dementia.	186
4.5.3. Appendix 3. Parkinson's disease	190

References	197
Index	217